Trial Profile
Phase II Trial of Imatinib (Gleevec) in Selected Patients With Metastatic Melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2013
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Acral lentiginous melanoma; Malignant melanoma
- Focus Therapeutic Use
- 14 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jan 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 22 Apr 2009 New trial record